COMMUNIQUÉS West-GlobeNewswire

Aptose Reports Results for the First Quarter Ended March 31, 2019
07/05/2019
─ Patient Dosed at Second Dose Level in APTO-253 Clinical Trial ─ ─ Patient Screening Initiated for CG-806 Clinical Trial ─ Conference Call and Webcast at 5pm EDT Today SAN DIEGO and TORONTO, May 07, 2019 (GLOBE [...]
Allakos Announces Positive Results with AK002 in Patients with Severe Allergic Conjunctivitis
07/05/2019
-- Substantial reduction of patient reported symptoms and physician assessed signs and symptoms -- -- Improvements also observed in atopic dermatitis, asthma and allergic rhinitis -- -- Conference call and webcast today [...]
New AveXis data at AAN showed long-term durability of Zolgensma® in patients with spinal muscular atrophy (SMA) Type 1
07/05/2019
Interim long-term follow-up data showed all enrolled Cohort 2 patients maintained motor function and milestones achieved during the Phase 1 START trial Mean age of follow-up since dosing with Zolgensma ( onasemnogene [...]
Trevi Therapeutics Announces Pricing of Initial Public Offering
07/05/2019
NEW HAVEN, Conn., May 07, 2019 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (“Trevi”), a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious [...]
NeuroMetrix Announces Issuance of New U.S. Patent for Quell Wearable Technology
07/05/2019
WALTHAM, Mass., May 07, 2019 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq:NURO) announced today that the U.S. Patent and Trademark Office has issued U.S. Patent No. 10,279,179 titled “Transcutaneous Electrical Nerve [...]
Medexus Pharmaceuticals Launches New Metoject® Subcutaneous 15mg Dosage for the Treatment of Rheumatoid Arthritis, Psoriasis and Psoriatic Arthritis in Canada
07/05/2019
MONTREAL, May 07, 2019 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP, OTCQB: PDDPF), today announced the launch of a new Metoject® Subcutaneous 15mg dose in Canada. Metoject [...]
ORION CORPORATION: ACQUISITION OF OWN SHARES 07.05.2019
07/05/2019
Orion Corporation NOTIFICATION 07.05.2019 at 18:30 ORION CORPORATION: ACQUISITION OF OWN SHARES 07.05.2019 Date 07.05.2019 Exchange transaction Buy Share class ORNBV Amount 30,832 Average price/share 29.6153 EUR Highest [...]
Dermatologists Say Sunscreen is a Vital Tool in the Fight Against Skin Cancer, the Most Common Cancer in the U.S.; American Academy of Dermatology
07/05/2019
During Skin Cancer Awareness Month, the American Academy of Dermatology is asking the public “Do you use protection?” and encouraging consumers to “practice safe sun” — which includes applying sunscreen ROSEMONT, Ill., [...]
Helsinn nominated as a Swiss Biotech Success Story 2019/2020 by the Swiss Biotech Association
07/05/2019
Helsinn nominated as a Swiss Biotech Success Story 2019/2020 by the Swiss Biotech Association Switzerland, May 7, 2019: Helsinn, a Swiss pharmaceutical group focused on building quality cancer care products, today [...]
Nelipak Healthcare Packaging and OPTEL Partner to Demonstrate New Seal Inspection Technology Concept for Vacuum-Formed Trays at MedtecLIVE 2019
07/05/2019
CRANSTON, R.I., May 07, 2019 (GLOBE NEWSWIRE) -- Nelipak ® Healthcare Packaging (“Nelipak”), a full-service global provider of custom thermoformed packaging that provides superior protection for medical devices and [...]
Ritter Pharmaceuticals Completes Dosing of Last Patient in Pivotal 557-Subject Phase 3 Clinical Trial of RP-G28 in Patients with Lactose Intolerance
07/05/2019
Top-line Data Readout on Target for early Q4 2019 LOS ANGELES, May 07, 2019 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of innovative [...]
Sanofi : Dupixent® (dupilumab) Approved for Severe Asthma by European Commission
07/05/2019
Dupixent ® (dupilumab) Approved for Severe Asthma by European Commission Only biologic approved in the EU for severe asthma with type 2 inflammation, as characterized by raised blood eosinophils and/or raised fractional [...]
Sanofi : Dupixent® (dupilumab) approuvé dans le traitement de l'asthme sévère par la Commission européenne
07/05/2019
Dupixent ® (dupilumab) approuvé dans le traitement de l'asthme sévère par la Commission européenne Seul médicament biologique approuvé dans l'UE pour le traitement de l'asthme sévère avec inflammation de type 2 [...]
Auris Medical Reaches Midpoint for Enrollment in AM-201 Phase 1b Proof-of-Concept Study in Antipsychotic-Induced Weight Gain
07/05/2019
Hamilton, Bermuda, May 07, 2019 (GLOBE NEWSWIRE) -- Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and [...]
CareDx’s AlloSeq cfDNA and QTYPE Solutions Featured at EFI 2019
07/05/2019
CareDx leadership in transplant innovation highlighted through multiple podium and poster presentations BRISBANE, Calif., May 07, 2019 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading molecular diagnostics [...]
CohBar Appoints Steven B. Engle as Chief Executive Officer
07/05/2019
MENLO PARK, Calif., May 07, 2019 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics (MBTs) to treat age-related diseases and extend healthy [...]
Adamis Pharmaceuticals Schedules First Quarter 2019 Earnings Conference Call and Business Update
07/05/2019
SAN DIEGO, May 07, 2019 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis”), a specialty biopharmaceutical company primarily focused on developing and commercializing products in various [...]
ImmuCell to Announce Unaudited Financial Results for First Quarter of 2019
07/05/2019
Conference Call Scheduled for Tuesday, May 14, 2019 at 9:00 AM ET PORTLAND, Maine, May 07, 2019 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”) - a growing animal health company [...]
TG Therapeutics Announces Long-term Follow-up Data from the Phase 2 Trial of Ublituximab in Patients with Multiple Sclerosis at the American Academy of Neurology 71st Annual Meeting
07/05/2019
Ublituximab treatment continues to be well tolerated with a median duration of follow-up of 97.5 weeks NEW YORK, May 07, 2019 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), a biopharmaceutical company [...]

Pages